| Name | Title | Contact Details |
|---|
Email how it is supposed to be: ✔ Free, simple and secure ✔ Manage multiple mail accounts in one place, from any device ✔ Sign up today!
From design to development to deployment, every NetCraftsmen® solution is implemented with un-matched technological expertise, and applied with a master…
Our Mission is to empower our customers by expanding their digital horizon. We help them through the vendor management portal & profit recovery audit services.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Welcome to Faraday, the smartest way to power B2C growth with real, actionable AI. See what you can achieve with Faradays end-to-end machine learning platform.